Literature DB >> 12472780

Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus.

Norman K Hollenberg1, Deborah A Price, Naomi D L Fisher, M Cecilia Lansang, Bruce Perkins, Michael S Gordon, Gordon H Williams, Lori M B Laffel.   

Abstract

BACKGROUND: Many studies have reported that blocking the renin-angiotensin-system (RAS) with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker in the patient with diabetes mellitus leads to an increase in renal plasma flow (RPF), no change in glomerular filtration rate (GFR), and a fall in filtration fraction. This constellation is generally attributed to predominant efferent arteriolar dilation.
METHODS: This study examined the renal hemodynamic response to blocking the RAS with both captopril and candesartan on separate days in 31 patients with type 1 diabetes mellitus.
RESULTS: There was a wide range of changes in RPF and GFR in response to the two agents, each administered at the top of its dose-response range. The RPF response to the two agents was strongly concordant (r = 0.65; P < 0.001), as was the GFR response (r = 0.81; P < 0.001). Moreover, there was a strong correlation between the RPF response and the change in GFR with each agent (r = 0.83 and 0.66; P < 0.01). A significant rise in RPF was followed by a rise in GFR. The RPF dependency of GFR in the type 1 diabetics suggests strongly that glomerular filtration equilibrium exists in the glomeruli of the diabetic kidney: Simple notions of local control based on afferent:efferent arteriolar resistance ratios are too simplistic.
CONCLUSION: Our data suggest that the intrarenal RAS is activated in over 80% of patients with type 1 diabetes mellitus. Abundant evidence suggests that this activation predisposes to diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12472780     DOI: 10.1046/j.1523-1755.2003.00701.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  30 in total

Review 1.  Dual Renin-Angiotensin-Aldosterone System Inhibition for the Treatment of Diabetic Kidney Disease: Adverse Effects and Unfulfilled Promise.

Authors:  Boutros El-Haddad; Scott Reule; Paul E Drawz
Journal:  Curr Diab Rep       Date:  2015-10       Impact factor: 4.810

2.  Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients?

Authors:  Norman K Hollenberg; Naomi D L Fisher; Juerg Nussberger; George V Moukarbel; Ebrahim Barkoudah; A H Jan Danser
Journal:  J Hypertens       Date:  2011-12       Impact factor: 4.844

3.  Renin gene polymorphism: its relationship to hypertension, renin levels and vascular responses.

Authors:  Bei Sun; Jonathan S Williams; Luminita Pojoga; Bindu Chamarthi; Jessica Lasky-Su; Benjamin A Raby; Paul N Hopkins; Xavier Jeunemaitre; Nancy J Brown; Claudio Ferri; Gordon H Williams
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2011-04-13       Impact factor: 1.636

Review 4.  Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease.

Authors:  Helmy M Siragy; Robert M Carey
Journal:  Am J Nephrol       Date:  2010-05-18       Impact factor: 3.754

5.  Below the radar: advanced glycation end products that detour "around the side". Is HbA1c not an accurate enough predictor of long term progression and glycaemic control in diabetes?

Authors:  Josephine M Forbes; Georgia Soldatos; Merlin C Thomas
Journal:  Clin Biochem Rev       Date:  2005-11

6.  A mechanism for salt-sensitive hypertension: abnormal dietary sodium-mediated vascular response to angiotensin-II.

Authors:  Bindu Chamarthi; Jonathan S Williams; Gordon H Williams
Journal:  J Hypertens       Date:  2010-05       Impact factor: 4.844

7.  Polymorphisms in the gene encoding angiotensin I converting enzyme 2 and diabetic nephropathy.

Authors:  S Fröjdö; L Sjölind; M Parkkonen; V-P Mäkinen; R Kilpikari; K Pettersson-Fernholm; C Forsblom; J Fagerudd; C Tikellis; M E Cooper; M Wessman; P-H Groop
Journal:  Diabetologia       Date:  2005-10-07       Impact factor: 10.122

8.  Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes.

Authors:  Julie A Lovshin; Geneviève Boulet; Yuliya Lytvyn; Leif E Lovblom; Petter Bjornstad; Mohammed A Farooqi; Vesta Lai; Leslie Cham; Josephine Tse; Andrej Orszag; Daniel Scarr; Alanna Weisman; Hillary A Keenan; Michael H Brent; Narinder Paul; Vera Bril; Bruce A Perkins; David Zi Cherney
Journal:  JCI Insight       Date:  2018-01-11

Review 9.  Application of direct renin inhibition to chronic kidney disease.

Authors:  Christian W Mende
Journal:  Cardiovasc Drugs Ther       Date:  2010-04       Impact factor: 3.727

10.  The effect of chronic candesartan therapy on the metabolic profile and renal tissue cytokine levels in the obese Zucker rat.

Authors:  Carolyn M Ecelbarger; Arjun Rash; Rajesh K Sinha; Swasti Tiwari
Journal:  Mediators Inflamm       Date:  2010-05-17       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.